Neurocrine Biosciences Tender Offer for Soleno Therapeutics Clears HSR Regulatory Hurdle
Summary
Neurocrine Biosciences announced that the waiting period under the HSR Act for its tender offer to acquire Soleno Therapeutics has expired, satisfying a key regulatory condition for the acquisition.
Key Events
-
HSR Act Waiting Period Expired
The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) applicable to the tender offer expired on April 27, 2026. This satisfies a key regulatory condition for the acquisition.
-
Tender Offer Progress
This amendment relates to the ongoing tender offer by Sigma Merger Sub, Inc., a subsidiary of Neurocrine Biosciences, to acquire all outstanding shares of Soleno Therapeutics for $53.00 per share in cash. The offer remains subject to other conditions.
Analysis
This amendment signals a significant step forward in the acquisition of Soleno Therapeutics by Neurocrine Biosciences. The expiration of the HSR Act waiting period satisfies a critical regulatory condition, substantially de-risking the tender offer. This increases the certainty that the acquisition will close as planned, providing clarity for Soleno shareholders regarding the $53.00 per share cash offer. Investors should monitor the remaining offer conditions and the tender period for further updates.
At the time of this filing, SLNO was trading at $52.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $29.43 to $90.32. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.